Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vishnu Sharma

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
BMC Rheumatology|June 11, 2020
Comparative evaluation of efficacy, pharmacodynamics, and safety of Hetero's adalimumab (Mabura®, Hetero Biopharma Ltd.) and reference adalimumab (Humira®, Abbvie Inc.) in patients with active rheumatoid arthritis on concomitant methotrexate therapyShubhadeep Sinha, Biswadip Ghosh, Syamasis Bandyopadhyay, et al.
Annals of the Rheumatic Diseases|July 17, 2020
Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from IndiaMohit Goyal, Pravin Patil, Himanshu Pathak, et al.
The Journal of the Association of Physicians of India|September 16, 2025
Comparison of the Efficacy and Safety of Biosimilar Adalimumab Injection with Innovator Adalimumab in Subjects with Active Ankylosing SpondylitisS Chandrashekara, Jyoti Ranjan Parida, Archana Sonawale, et al.
Plos One|January 2, 2024
Perfusion vs non-perfusion computed tomography imaging in the late window of emergent large vessel ischemic stroke: A systematic review and meta-analysisJose Danilo B Diestro, Abdelsimar T Omar, Yu-Qing Zhang, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
BMC Rheumatology|June 11, 2020
Comparative evaluation of efficacy, pharmacodynamics, and safety of Hetero's adalimumab (Mabura®, Hetero Biopharma Ltd.) and reference adalimumab (Humira®, Abbvie Inc.) in patients with active rheumatoid arthritis on concomitant methotrexate therapyShubhadeep Sinha, Biswadip Ghosh, Syamasis Bandyopadhyay, et al.
Annals of the Rheumatic Diseases|July 17, 2020
Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from IndiaMohit Goyal, Pravin Patil, Himanshu Pathak, et al.
The Journal of the Association of Physicians of India|September 16, 2025
Comparison of the Efficacy and Safety of Biosimilar Adalimumab Injection with Innovator Adalimumab in Subjects with Active Ankylosing SpondylitisS Chandrashekara, Jyoti Ranjan Parida, Archana Sonawale, et al.
Plos One|January 2, 2024
Perfusion vs non-perfusion computed tomography imaging in the late window of emergent large vessel ischemic stroke: A systematic review and meta-analysisJose Danilo B Diestro, Abdelsimar T Omar, Yu-Qing Zhang, et al.
Pageof 7